| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |